Capital raised by Cime Therapeutics
1 Form D filing · first filed Mar 2025 · Denver, CO
Chief Executive Officer
Signatory on Cime Therapeutics's Form D filings · $2.1M raised across 1
James Thomas Brewster II is on file as Chief Executive Officer at Cime Therapeutics in Denver, CO. Cime Therapeutics has 1 Form D filing on record, $2.1M raised in total. James Thomas Brewster II appears as a signatory on the company's filings.
The SCIP platform is an innovative technology that develops modified variants of cell surface proteins in hematopoietic stem cells (HSCs). These modifications allow the cells to maintain their essential functions while resisting depletion from immunotherapies. Furthermore, the platform features paired immunotherapies that selectively target and deplete diseased cells, ensuring that the shielded healthy cells remain unharmed.
